ArticleWorld journal of gastroenterology2009
Inhibitory effect of emodin and Astragalus polysaccharide on the replication of HBV.
Article in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- The Invasive SpeciesFrontiers in pharmacology · 2022Pooled it
- Traditional Chinese Medicine in Chronic Hepatitis B: Integrating Antiviral Effects and Immune Modulation in the Context of T Cell Exhaustion.Drug design, development and therapy · 2026Review
- Antiviral Activity of Liposomes Containing Natural Compounds Against CHIKV.Pharmaceutics · 2025Article
- Therapeutic Potential of Emodin: A Mini-Review of Its Anti-Biofilm and Antimicrobial Effects.Infectious disorders drug targets · 2025Review
- Biosynthesis and Pharmacological Activities of Flavonoids, Triterpene Saponins and Polysaccharides Derived fromMolecules (Basel, Switzerland) · 2023Review
- Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.International journal of molecular sciences · 2023Article
- Antiviral Potential of Plants against COVID-19 during Outbreaks-An Update.International journal of molecular sciences · 2022Review
- Article
- Emodin Attenuates Acetaminophen-Induced Hepatotoxicity via the cGAS-STING Pathway.Inflammation · 2022Article
- Promising Role of Emodin as Therapeutics to Against Viral Infections.Frontiers in pharmacology · 2022Review
- Autophagic Inhibition of Caveolin-1 by CompoundFrontiers in pharmacology · 2021Article
- Safe-in-Man Broad Spectrum Antiviral Agents.Advances in experimental medicine and biology · 2021Article
- Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines.International journal of biological macromolecules · 2020Review
- Article
- Astragalus membranaceus (Fisch.) Bunge repairs intestinal mucosal injury induced by LPS in mice.BMC complementary and alternative medicine · 2018Article
- Compound of icariin, astragalus, and puerarin mitigates iron overload in the cerebral cortex of Alzheimer's disease mice.Neural regeneration research · 2018Article
- Astragalus polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication.Microbial pathogenesis · 2018Article
- Recent Advances in Herbal Medicines for Digestive System Malignancies.Frontiers in pharmacology · 2018Review
- Emodin Inhibition of Influenza A Virus Replication and Influenza Viral Pneumonia via the Nrf2, TLR4, p38/JNK and NF-kappaB Pathways.Molecules (Basel, Switzerland) · 2017Article
- Astragalus polysaccharides attenuate PCV2 infection by inhibiting endoplasmic reticulum stress in vivo and in vitro.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the anti-viral effect of emodin plus Astragalus polysaccharide (APS) in hepatitis B virus (HBV) transgenic mice.
methodsSixty HBV transgenic mice (HBV TGM) whose weight varied between 18 and 24 g were randomly divided into 3 groups, with 20 mice in each group. Group A was the normal control, where the mice were treated with physiological saline; group B was the positive control where the mice were treated with lamivudine solution (100 mL/kg per day). Group C was the experimental group where the mice were treated with physiological saline containing emodin and APS (57.59 mg/kg per day and 287.95 mg/kg per day, respectively). The mice were treated daily for 3 wk. After 1 wk recovery time, the mice were sacrificed and serum as well as liver tissues were collected for ELISA and histological examination.
resultsAfter 21 d treatment, HBV DNA levels in group B and group C significantly declined when compared with group A (P < 0.05). However, a significant increase in HBV DNA content was observed in group B, whereas this phenomenon was not observed in group C. A reduction in the contents of HBsAg, HBeAg and HBcAg in the mice from group B and C was observed when compared with group A.
conclusionEmodin and APS have a weak but persistent inhibitory effect on HBV replication in vivo, which may function as a supplementary modality in the treatment of hepatitis B infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.